A Comparison of the Potential Public Health Impact of PCV15 and PCV20 in French Infants
Author(s)
Aleksandar Ilic, MSc1, Sophie Warren, MSc2, Stephane Fievez, PhD3, Emmanuelle Blanc, PhD3, Maud beillat, BA3, Ayman Sabra, PhD3, Mark Rozenbaum, MBA, PhD4.
1Pfizer, London, United Kingdom, 2Pfizer, Cambridge, MA, USA, 3Pfizer, Paris, France, 4Pfizer, Capelle aan den IJssel, Netherlands.
1Pfizer, London, United Kingdom, 2Pfizer, Cambridge, MA, USA, 3Pfizer, Paris, France, 4Pfizer, Capelle aan den IJssel, Netherlands.
OBJECTIVES: In Europe, PCV20 is licensed for use in infants in a 3+1 schedule (three priming doses + one booster dose), while PCV15 is licensed for use in infants in a 2+1 schedule (two priming doses + one booster). Both PCV15 and PCV20 are available in France, but only PCV15 is recommended. This analysis compared the potential public health impact of PCV15 and PCV20 on pneumococcal disease in French infants during their first year of life.
METHODS: A decision-analytic model estimated the number of invasive pneumococcal disease (IPD) cases averted with PCV20 or PCV15 in children <1 year old across five annual birth cohorts. Epidemiological inputs were sourced from published literature. Vaccine effectiveness (VE) was extrapolated from PCV13 effectiveness and PCV7 efficacy studies. The model did not consider indirect effects. Although the relationship between immunogenicity and clinical VE is not well established, a scenario analysis was conducted using VE estimates based on immunogenicity data published by Bakker et al. (2025) and Wong et al. (2025). Additional scenarios explored the impact on hospitalized pneumonia and hospitalized otitis media (OM) and a two-dose priming series for PCV20.
RESULTS: If impact is limited to the first year of life, PCV20 vaccination could prevent an additional 97 IPD cases, 1,515 inpatient pneumonia cases, and 406 inpatient OM cases compared to PCV15 across 5 birth cohorts. PCV20 implementation could also prevent 18 pneumococcal-associated deaths among French infants. These findings were consistent in the two-dose priming series scenario. When using VE based on immunogenicity data, PCV20 continued to demonstrate greater impact, preventing 22 more IPD cases versus PCV15.
CONCLUSIONS: PCV20 vaccination is projected to provide greater protection against pneumococcal disease in French infants than PCV15, regardless of VE assumptions or dosing schedules. These results support the preferential use of PCV20 to maximize disease prevention in the first year of life.
METHODS: A decision-analytic model estimated the number of invasive pneumococcal disease (IPD) cases averted with PCV20 or PCV15 in children <1 year old across five annual birth cohorts. Epidemiological inputs were sourced from published literature. Vaccine effectiveness (VE) was extrapolated from PCV13 effectiveness and PCV7 efficacy studies. The model did not consider indirect effects. Although the relationship between immunogenicity and clinical VE is not well established, a scenario analysis was conducted using VE estimates based on immunogenicity data published by Bakker et al. (2025) and Wong et al. (2025). Additional scenarios explored the impact on hospitalized pneumonia and hospitalized otitis media (OM) and a two-dose priming series for PCV20.
RESULTS: If impact is limited to the first year of life, PCV20 vaccination could prevent an additional 97 IPD cases, 1,515 inpatient pneumonia cases, and 406 inpatient OM cases compared to PCV15 across 5 birth cohorts. PCV20 implementation could also prevent 18 pneumococcal-associated deaths among French infants. These findings were consistent in the two-dose priming series scenario. When using VE based on immunogenicity data, PCV20 continued to demonstrate greater impact, preventing 22 more IPD cases versus PCV15.
CONCLUSIONS: PCV20 vaccination is projected to provide greater protection against pneumococcal disease in French infants than PCV15, regardless of VE assumptions or dosing schedules. These results support the preferential use of PCV20 to maximize disease prevention in the first year of life.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH1
Topic
Epidemiology & Public Health
Topic Subcategory
Public Health
Disease
Pediatrics, Vaccines